Sarepta Therapeutics’ (SRPT) “Outperform” Rating Reaffirmed at Raymond James

Raymond James reissued their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report sent to investors on Thursday, Marketbeat reports. They currently have a $150.00 price target on the biotechnology company’s stock.

Several other research firms have also recently commented on SRPT. Cantor Fitzgerald reaffirmed a neutral rating and issued a $152.00 target price on shares of Sarepta Therapeutics in a research report on Friday, September 20th. Bank of America lifted their price target on Sarepta Therapeutics from $166.00 to $213.00 and gave the company a buy rating in a research report on Friday, June 21st. Morgan Stanley reiterated an overweight rating and issued a $165.00 price objective on shares of Sarepta Therapeutics in a report on Friday, June 21st. BMO Capital Markets lifted their price target on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an outperform rating in a research report on Monday, June 24th. Finally, William Blair upgraded shares of Sarepta Therapeutics to a strong-buy rating in a report on Friday, August 30th. Two equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus target price of $185.47.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock opened at $124.51 on Thursday. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. Sarepta Therapeutics has a one year low of $55.25 and a one year high of $173.25. The stock has a market capitalization of $11.77 billion, a P/E ratio of 1,131.91 and a beta of 0.82. The business’s 50 day simple moving average is $130.19 and its two-hundred day simple moving average is $132.51.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. The firm had revenue of $362.90 million for the quarter, compared to analysts’ expectations of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.27) earnings per share. Analysts forecast that Sarepta Therapeutics will post 1.45 EPS for the current year.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Michael Andrew Chambers bought 37,038 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were bought at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the transaction, the director now owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Sarepta Therapeutics by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock worth $850,139,000 after purchasing an additional 243,180 shares in the last quarter. Capital International Investors raised its holdings in Sarepta Therapeutics by 1.6% during the first quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock valued at $623,676,000 after acquiring an additional 76,032 shares during the period. Wellington Management Group LLP lifted its position in shares of Sarepta Therapeutics by 5.6% in the fourth quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company’s stock valued at $398,025,000 after acquiring an additional 217,810 shares in the last quarter. Farallon Capital Management LLC boosted its stake in shares of Sarepta Therapeutics by 102.8% in the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after acquiring an additional 1,243,427 shares during the period. Finally, Thrivent Financial for Lutherans grew its position in shares of Sarepta Therapeutics by 6.3% during the second quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock worth $101,858,000 after purchasing an additional 37,940 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.